Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.
Journal: Annals of the rheumatic diseases
Published: July 15, 2025
Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound.
Journal: Clinical and experimental rheumatology
Published: September 15, 2020
The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation.
Journal: The European respiratory journal
Published: January 17, 2019
Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: December 20, 2018
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Journal: Annals of the rheumatic diseases
Published: November 10, 2018
A high-throughput antibody-based microarray typing platform.
Journal: Sensors (Basel, Switzerland)
Published: February 22, 2013
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
Journal: Journal of drugs in dermatology : JDD
Published: November 09, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026